These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 3480803)

  • 1. Idarubicin in combination with etoposide and cytarabine in adult untreated acute non lymphoblastic leukemia.
    Carella AM; Martinengo M; Santini G; Gaozza E; Damasio E; Giordano D; Nati S; Congiu A; Cerri R; Risso M
    Eur J Cancer Clin Oncol; 1987 Nov; 23(11):1673-8. PubMed ID: 3480803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A New Combination of Idarubicin, Etoposide and Cytarabine in Untreated Acute Non-Lymphoblastic Leukemia.
    Carella AM; Gaozza E; Piatti G; Nati S; Pungoltno E; Santini G; Giordano D; Cerri R; Risso M; Rossi E; Spriano M; Coingiu A; Carlier P; Raffo MR; Damagio E; Bacigalupo A; Marmont AM
    Leuk Lymphoma; 1990; 2(5):317-22. PubMed ID: 27456922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel multiagent chemotherapy for bone marrow relapse of pediatric acute lymphoblastic leukemia.
    Leahey AM; Bunin NJ; Belasco JB; Meek R; Scher C; Lange BJ
    Med Pediatr Oncol; 2000 May; 34(5):313-8. PubMed ID: 10797352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Idarubicin in sequential combination with cytosine arabinoside in the treatment of relapsed and refractory patients with acute non-lymphoblastic leukemia.
    Lambertenghi-Deliliers G; Maiolo AT; Annaloro C; Cortelezzi A; Pogliani E; Ganzina F; Polli EE
    Eur J Cancer Clin Oncol; 1987 Jul; 23(7):1041-5. PubMed ID: 3478198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination chemotherapy of intermediate-dose cytarabine, idarubicin, plus etoposide and subsequent mobilized donor leukocyte infusion for relapsed acute leukemia after allogeneic bone marrow transplantation.
    Lee JH; Lee KH; Kim S; Seol M; Kim SH; Kim WK; Lee JS
    Leuk Res; 2001 Apr; 25(4):305-12. PubMed ID: 11248327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Intensification chemotherapy followed by allogenieic and autologous bone marrow transplantation in acute non-lymphoblastic leukemia in children].
    Ortega Aramburu JJ; Olivé Oliveras T; Javier Manchón G; Bastida Vila P; Sánchez C; Giralt López J
    Sangre (Barc); 1991 Feb; 36(1):7-14. PubMed ID: 1853274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A systematic overview of chemotherapy effects in acute myeloid leukaemia.
    Kimby E; Nygren P; Glimelius B;
    Acta Oncol; 2001; 40(2-3):231-52. PubMed ID: 11441935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Idarubicin in refractory acute leukemia.
    Fülle HH; Hellriegel KP
    Onkologie; 1986 Jun; 9(3):152-3. PubMed ID: 3528962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Results of treatment with an intensive combination induction regimen containing idarubicin in children with acute myeloblastic leukemia: preliminary report of the Argentine Group for Treatment of Acute Leukemia.
    Sackmann-Muriel F; Fernández-Barbieri MA; Santarelli MT; Matus-Ridley M; Rosso A; Negri-Aranguren P; Cerutti I; Gomel M; Kvicala R
    Semin Oncol; 1993 Dec; 20(6 Suppl 8):34-8. PubMed ID: 8290970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Idarubicin alone or in combination with cytarabine and etoposide (3 + 3 + 5 protocol) in acute non-lymphoblastic leukaemia.
    Carella AM; Santini G; Giordano D; Frassoni F; Martinengo M; Congiu A; Nati S; Risso M; Cerri R; Marmont A
    Leuk Res; 1985; 9(5):631. PubMed ID: 3859711
    [No Abstract]   [Full Text] [Related]  

  • 11. Autologous bone marrow transplantation vs intensive chemotherapy in first complete remission: interim results of GOELAM study in AML.
    Harousseau JL; Pignon B; Dufour P; Ifrah N; Solary E; Abgrall JF; Milpied N; Desablens B; Guyotat D; Herve P
    Leukemia; 1992; 6 Suppl 2():120-3. PubMed ID: 1578912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDS of more than 6 months duration. A pilot study by the Leukemia Cooperative Group of the European Organisation for Research and Treatment in Cancer (EORTC-LCG).
    de Witte T; Suciu S; Peetermans M; Fenaux P; Strijckmans P; Hayat M; Jaksic B; Selleslag D; Zittoun R; Dardenne M
    Leukemia; 1995 Nov; 9(11):1805-11. PubMed ID: 7475266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral idarubicin in combination with cytosine-arabinoside in previously untreated patients with acute non-lymphocytic leukemia.
    Falkson G; Coccia-Portugal MA; Vorobiof DA; Terblanche AP; Dreyer R
    Am J Clin Oncol; 1986 Aug; 9(4):311-4. PubMed ID: 3463190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Idarubicin, high-dose cytarabine, and etoposide for induction of remission in acute leukemia.
    Mehta J; Powles R; Singhal S; Horton C; Hamblin M; Zomas A; Saso R; Prendiville J; Glynne P; Allford S; Mackay H; Treleaven J
    Semin Hematol; 1996 Oct; 33(4 Suppl 3):18-23. PubMed ID: 8916312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
    Hofmann WK; Heil G; Zander C; Wiebe S; Ottmann OG; Bergmann L; Hoeffken K; Fischer JT; Knuth A; Kolbe K; Schmoll HJ; Langer W; Westerhausen M; Koelbel CB; Hoelzer D; Ganser A
    Ann Hematol; 2004 Aug; 83(8):498-503. PubMed ID: 15156346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Remission induction therapy of untreated acute myeloid leukemia using a non-cytarabine-containing regimen of idarubicin, etoposide, and carboplatin.
    Bow EJ; Gallant G; Williams GJ; Woloschuk D; Shore TB; Rubinger M; Schacter BA
    Cancer; 1998 Oct; 83(7):1344-54. PubMed ID: 9762935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Idarubicin/cytosine arabinoside and mitoxantrone/etoposide for the treatment of de novo acute myelogenous leukemia.
    Haas R; Ho AD; Del Valle F; Fischer JT; Ehrhardt R; Döhner H; Witt B; Huberts H; Kaplan E; Hunstein W
    Semin Oncol; 1993 Dec; 20(6 Suppl 8):20-6. PubMed ID: 8290968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I/II study of intensive dose escalation of cytarabine in combination with idarubicin and etoposide in induction and consolidation treatment of adult acute myeloid leukemia. Australian Leukaemia Study Group (ALSG).
    Lowenthal RM; Bradstock KF; Matthews JP; Bishop JF; Juneja S; Cobcroft R; Eliadis P; Enno A; Gill D; Herrmann RP; Manoharan A; Page FJ; Rooney KF; Rosenfeld D; Seldon M; Taylor KM; Wolf MM; Young GA
    Leuk Lymphoma; 1999 Aug; 34(5-6):501-10. PubMed ID: 10492073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autologous bone marrow transplantation in late first complete remission improves outcome in acute myelogenous leukemia.
    Miggiano MC; Gherlinzoni F; Rosti G; Bandini G; Visani G; Fiacchini M; Ricci P; Testoni N; Motta MR; Geromin A; Rizzi S; Belardinelli A; Mangianti S; Manfroi S; Tura S
    Leukemia; 1996 Mar; 10(3):402-9. PubMed ID: 8642854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of Reduced-Intensity Idarubicin and Daunorubicin Plus Cytarabine as Induction Chemotherapy for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia.
    Liu H; Fu R; Li L; Wang G; Song J; Ruan E; Wang H; Wu Y; Wang X; Ding K; Shao Z
    Clin Drug Investig; 2017 Feb; 37(2):167-174. PubMed ID: 27722823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.